{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:13:17Z","timestamp":1785841997009,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Polish National Science Centre","doi-asserted-by":"crossref","award":["2020\/39\/D\/NZ2\/03106"],"award-info":[{"award-number":["2020\/39\/D\/NZ2\/03106"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004281","name":"Polish National Science Centre","doi-asserted-by":"crossref","award":["2016\/22\/A\/NZ2\/00184"],"award-info":[{"award-number":["2016\/22\/A\/NZ2\/00184"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent data indicate that <jats:italic>MIR142<\/jats:italic> is the most frequently mutated miRNA gene and one of the most frequently mutated noncoding elements in all cancers, with mutations occurring predominantly in blood cancers, especially diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Functional analyses show that the <jats:italic>MIR142<\/jats:italic> alterations have profound consequences for lympho- and myelopoiesis. Furthermore, one of the targets downregulated by miR-142-5p is <jats:italic>CD274<\/jats:italic>, which encodes PD-L1 that is elevated in many cancer types, including myeloproliferative neoplasms (MPNs). To extend knowledge about the occurrence of <jats:italic>MIR142<\/jats:italic> mutations, we sequenced the gene in a large panel of MPNs [~\u2009700 samples, including polycythemia vera, essential thrombocythemia, primary myelofibrosis (PMF), and chronic myeloid leukemia], neoplasm types in which such mutations have never been tested, and in panels of acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). We identified 3 mutations (one in a PMF sample and two others in one CLL sample), indicating that <jats:italic>MIR142<\/jats:italic> mutations are rare in MPNs. In summary, mutations in <jats:italic>MIR142<\/jats:italic> are rare in MPNs; however, in specific subtypes, such as PMF, their frequency may be comparable to that observed in CLL or AML.<\/jats:p>","DOI":"10.1038\/s41598-022-15162-1","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T18:04:08Z","timestamp":1656439448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mutations in the miR-142 gene are not common in myeloproliferative neoplasms"],"prefix":"10.1038","volume":"12","author":[{"given":"Paulina","family":"Galka-Marciniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Kandu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladyslaw","family":"Wegorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Gwozdz-Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Handschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Giefing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"15162_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00371-z","author":"K Elliott","year":"2021","unstructured":"Elliott, K. & Larsson, E. Non-coding driver mutations in human cancer. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/s41568-021-00371-z (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"15162_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103084","volume":"61","author":"H Tan","year":"2020","unstructured":"Tan, H. Somatic mutation in noncoding regions: The sound of silence. EBioMedicine 61, 103084 (2020).","journal-title":"EBioMedicine"},{"key":"15162_CR3","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"Vinagre, J. et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013).","journal-title":"Nat. Commun."},{"key":"15162_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103051","volume":"61","author":"MO Urbanek-Trzeciak","year":"2020","unstructured":"Urbanek-Trzeciak, M. O. et al. Pan-cancer analysis of somatic mutations in miRNA genes. EBioMedicine 61, 103051 (2020).","journal-title":"EBioMedicine"},{"key":"15162_CR5","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1158\/0008-5472.CAN-17-3592","volume":"78","author":"MC Trissal","year":"2018","unstructured":"Trissal, M. C. et al. MIR142 loss-of-function mutations derepress ASH1L to Increase HOXA gene expression and promote leukemogenesis. Cancer Res. 78, 3510\u20133521 (2018).","journal-title":"Cancer Res."},{"key":"15162_CR6","doi-asserted-by":"publisher","first-page":"19390","DOI":"10.1038\/s41598-020-76218-8","volume":"10","author":"A Marshall","year":"2020","unstructured":"Marshall, A. et al. Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes. Sci. Rep. 10, 19390 (2020).","journal-title":"Sci. Rep."},{"key":"15162_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cam4.29","volume":"1","author":"W Kwanhian","year":"2012","unstructured":"Kwanhian, W. et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med. 1, 141\u2013155 (2012).","journal-title":"Cancer Med."},{"key":"15162_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12032-013-0527-6","volume":"30","author":"FM Tolba","year":"2013","unstructured":"Tolba, F. M., Foda, M. E., Kamal, H. M. & Elshabrawy, D. A. Expression of CD133 in acute leukemia. Med. Oncol. Northwood Lond. Engl. 30, 527 (2013).","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"15162_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00109-013-1037-x","volume":"91","author":"W-W Shen","year":"2013","unstructured":"Shen, W.-W., Zeng, Z., Zhu, W.-X. & Fu, G.-H. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J. Mol. Med. Berl. Ger. 91, 989\u20131000 (2013).","journal-title":"J. Mol. Med. Berl. Ger."},{"key":"15162_CR10","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2014-10-603951","volume":"125","author":"NJ Kramer","year":"2015","unstructured":"Kramer, N. J. et al. Altered lymphopoiesis and immunodeficiency in miR-142 null mice. Blood 125, 3720\u20133730 (2015).","journal-title":"Blood"},{"key":"15162_CR11","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1038\/ncomms9523","volume":"6","author":"S Su","year":"2015","unstructured":"Su, S. et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat. Commun. 6, 8523 (2015).","journal-title":"Nat. Commun."},{"key":"15162_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2019.06.016","volume":"51","author":"MM Berrien-Elliott","year":"2019","unstructured":"Berrien-Elliott, M. M. et al. MicroRNA-142 is critical for the homeostasis and function of type 1 innate lymphoid cells. Immunity 51, 479-490.e6 (2019).","journal-title":"Immunity"},{"key":"15162_CR13","first-page":"4114","volume":"22","author":"L Zhou","year":"2016","unstructured":"Zhou, L. et al. Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 synergistically compromise immune defense of host cells in EBV-positive burkitt lymphoma. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 22, 4114\u20134120 (2016).","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"15162_CR14","first-page":"272","volume":"40","author":"J Wan","year":"2018","unstructured":"Wan, J., Ling, X., Peng, B. & Ding, G. miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway. Oncol. Rep. 40, 272\u2013282 (2018).","journal-title":"Oncol. Rep."},{"key":"15162_CR15","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1182\/blood-2010-12-325647","volume":"117","author":"Y Sun","year":"2011","unstructured":"Sun, Y. et al. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood 117, 6172\u20136183 (2011).","journal-title":"Blood"},{"key":"15162_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bbrc.2017.05.074","volume":"488","author":"L Jia","year":"2017","unstructured":"Jia, L. et al. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem. Biophys. Res. Commun. 488, 425\u2013431 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"15162_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.biopha.2017.11.058","volume":"97","author":"J Zhen","year":"2018","unstructured":"Zhen, J. & Chen, W. MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice. Biomed. Pharmacother. Biomedecine Pharmacother. 97, 1479\u20131485 (2018).","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"15162_CR18","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino, A. et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 10, 7729 (2018).","journal-title":"Sci. Transl. Med."},{"key":"15162_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13577-020-00370-6","volume":"33","author":"SA Guru","year":"2020","unstructured":"Guru, S. A. et al. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum. Cell 33, 1099\u20131111 (2020).","journal-title":"Hum. Cell"},{"key":"15162_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","volume":"136","author":"TS Larsen","year":"2007","unstructured":"Larsen, T. S., Christensen, J. H., Hasselbalch, H. C. & Pallisgaard, N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br. J. Haematol. 136, 745\u2013751 (2007).","journal-title":"Br. J. Haematol."},{"key":"15162_CR21","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard, E. et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17, 2474\u20132486 (2003).","journal-title":"Leukemia"},{"key":"15162_CR22","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379\u20132390 (2013).","journal-title":"N. Engl. J. Med."},{"key":"15162_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","volume":"149","author":"EM Boyd","year":"2010","unstructured":"Boyd, E. M. et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br. J. Haematol. 149, 250\u2013257 (2010).","journal-title":"Br. J. Haematol."},{"key":"15162_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115693","volume":"9","author":"J Lin","year":"2014","unstructured":"Lin, J. et al. Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome. PLoS ONE 9, e115693 (2014).","journal-title":"PLoS ONE"},{"key":"15162_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045760","volume":"7","author":"J Qian","year":"2012","unstructured":"Qian, J. et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 7, e45760 (2012).","journal-title":"PLoS ONE"},{"key":"15162_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160489","volume":"11","author":"R Hatae","year":"2016","unstructured":"Hatae, R. et al. Precise detection of IDH1\/2 and BRAF hotspot mutations in clinical glioma tissues by a differential calculus analysis of high-resolution melting data. PLoS ONE 11, e0160489 (2016).","journal-title":"PLoS ONE"},{"key":"15162_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2011.051532","volume":"97","author":"M Pratcorona","year":"2012","unstructured":"Pratcorona, M. et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 97, 388\u2013392 (2012).","journal-title":"Haematologica"},{"key":"15162_CR28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","volume":"145","author":"V Gelsi-Boyer","year":"2009","unstructured":"Gelsi-Boyer, V. et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145, 788\u2013800 (2009).","journal-title":"Br. J. Haematol."},{"key":"15162_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519\u2013524 (2015).","journal-title":"Nature"},{"key":"15162_CR30","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.3324\/haematol.2014.120345","volume":"100","author":"F Thol","year":"2015","unstructured":"Thol, F. et al. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica 100, e122\u2013e124 (2015).","journal-title":"Haematologica"},{"key":"15162_CR31","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","DOI":"10.1056\/NEJMoa1301689"},{"key":"15162_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-017-0040-5","volume":"3","author":"H Hornsh\u00f8j","year":"2018","unstructured":"Hornsh\u00f8j, H. et al. Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. NPJ Genomic Med. 3, 1 (2018).","journal-title":"NPJ Genomic Med."},{"key":"15162_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018101153","volume":"38","author":"J Sheu-Gruttadauria","year":"2019","unstructured":"Sheu-Gruttadauria, J., Xiao, Y., Gebert, L. F. & MacRae, I. J. Beyond the seed: structural basis for supplementary microRNA targeting by human Argonaute2. EMBO J. 38, e101153 (2019).","journal-title":"EMBO J."},{"key":"15162_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.tig.2018.12.005","volume":"35","author":"LB Chipman","year":"2019","unstructured":"Chipman, L. B. & Pasquinelli, A. E. miRNA Targeting: Growing beyond the Seed. Trends Genet. TIG 35, 215\u2013222 (2019).","journal-title":"Trends Genet. TIG"},{"key":"15162_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cancers11060793","volume":"11","author":"P Galka-Marciniak","year":"2019","unstructured":"Galka-Marciniak, P. et al. Somatic mutations in miRNA genes in lung cancer\u2014potential functional consequences of non-coding sequence variants. Cancers 11, 793 (2019).","journal-title":"Cancers"},{"key":"15162_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.101023","volume":"3","author":"MO Urbanek-Trzeciak","year":"2022","unstructured":"Urbanek-Trzeciak, M. O., Kozlowski, P. & Galka-Marciniak, P. miRMut: Annotation of mutations in miRNA genes from human whole-exome or whole-genome sequencing. STAR Protoc. 3, 101023 (2022).","journal-title":"STAR Protoc."},{"key":"15162_CR37","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","volume":"31","author":"M Zuker","year":"2003","unstructured":"Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406\u20133415 (2003).","journal-title":"Nucleic Acids Res."},{"key":"15162_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks339","volume":"40","author":"M Popenda","year":"2012","unstructured":"Popenda, M. et al. Automated 3D structure composition for large RNAs. Nucleic Acids Res. 40, e112 (2012).","journal-title":"Nucleic Acids Res."},{"key":"15162_CR39","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28, 1472\u20131477 (2014).","journal-title":"Leukemia"},{"key":"15162_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/0008-5472.CAN-21-2930","volume":"82","author":"A Tefferi","year":"2022","unstructured":"Tefferi, A., Gangat, N., Pardanani, A. & Crispino, J. D. Myelofibrosis: genetic characteristics and the emerging therapeutic landscape. Cancer Res. 82, 749\u2013763 (2022).","journal-title":"Cancer Res."},{"key":"15162_CR41","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32, 1631\u20131642 (2018).","journal-title":"Leukemia"},{"key":"15162_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2013.286","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 28, 431\u2013433 (2014).","journal-title":"Leukemia"},{"key":"15162_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/leu.2011.253","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi, A. et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26, 475\u2013480 (2012).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15162-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:31:52Z","timestamp":1669357912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15162-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15162"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15162-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10924"}}